All In MedTech

FDA Clearance Tracker · P250033-S002

NEXUS Aortic Arch Stent Graft System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 24, 2026

Approved

Time to decision

85 days

Received Apr 30, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P250033-S002
Device name
NEXUS Aortic Arch Stent Graft System
Applicant location
Alta, WY
Received
Apr 30, 2026
Decided
Jul 24, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P250033

Device type

Device class
Class III

Every decision under product code SDZ

FDA's approval statement

As written in FDA's record.

approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250033.

Source documents

Other decisions for Endospan , Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.